Who
Colleen F. Reitan
Director
Company insider
Files Form 4 as: Director, Myriad Genetics; Director, Alnylam Pharmaceuticals.
In numbers
- Trades disclosed
- 44
- Buys
- 2
- Sells
- 3
- Bought
- $10K
- Sold
- $9.7M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 1 Jun 2018
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —59,701 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —59,701 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —671 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,441 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,441 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —671 at $0.00 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,000 at $0.00 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $1.8M18,000 at $100.65 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $752K1,645 at $457.44 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $866K1,888 at $458.86 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $645K1,403 at $459.73 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $218K473 at $460.71 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.1M2,290 at $461.92 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $765K1,652 at $463.00 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $371K799 at $464.36 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $105K222 at $471.25 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $389K823 at $472.82 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $397K838 at $474.22 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $452K951 at $474.85 | filing |
| 9 Sep 2025filed 11 Sep 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $463K972 at $476.31 | filing |
News
Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)MYGN · tickerreport.com · 20 Oct 2026Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing BusinessMYGN · investorideas.com · 20 Oct 2026FinancialContent - Myriad Genetics (MYGN) Stock Trades Up, Here Is WhyMYGN · financialcontent.com · 20 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) and TScan Therapeutics (NASDAQ:TCRX) Critical SurveyALNY · themarketsdaily.com · 20 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyALNY · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Colleen F. Reitan; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.